Publications

References for ToxNav and ColoTox

  1. Church D, Kerr R, Domingo E, Rosmarin D, Palles C, Maskell K, Tomlinson I, Kerr D. ‘Toxgnostics’: an unmet need in cancer medicine. Nat Rev Cancer;14(6):440-5. 2014 Jun.
  2. Dan Rosmarin et al A candidate gene study of capecitabine-related toxicity identifies three new DPYD toxicity variants and a putative role for ENOSF1 rather than TYMS, Gut, Mar 19 [Epub ahead of print]
  3. Dan Rosmarin et al Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis Dan Rosmarin, J Clinical Oncology Apr 1, 2014:1031-1039.
  4. Midgley R, Kerr DJ. Capecitabine: have we got the right dose? Nature Clinical Practice. Vol 6: 1, 17-24. Oct 2008.
  5. Chan, R and Kerr DJ. Can we individualise chemotherapy for colorectal cancer? Annals of Oncology. 15, 996-999, July 2004.

References for ColoProg

  1. David J. Kerr & Yuankai Shi Biological markers: Tailoring treatment and trials to prognosis Nature Reviews Clinical Oncology 10, 429-430, August 2013.
  2. Enric Domingo, David N. Church⇑, Oliver Sieber, Rajarajan Ramamoorthy, Yoko Yanagisawa, Elaine Johnstone, Brian Davidson, David J. Kerr, Ian P.M. Tomlinson and Rachel Midgley Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer, J Clinical Oncology, 2013:4297-4305.
  3. Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O, Tomlinson I. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229(3):441-448. 2013.
  4. Quirke P, Hutchins G, Southward K, Hardley K, Magill L, Beaumont C, Stahlschmidt J, Rickman S, Chambers P, Seymour M, Gray R and Kerr DJ. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol,:1261-1270. 2011.
  5. Salazar R, Roepman P, Capella G, Moreno V, Simon I, López-Doriga1 A, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, M Glas A, Van ’t Veer L and Tollenaar R. A Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. J Clin Oncol, 1,17-24. 2011.
  6. Gray R, Quirke P, Hardley K, Lopatin M, Magill L, aehner FL, Beaumont C, Clark-Langore KM, Yoshiwarza CN, Lee M, Watson D, Shak S and Kerr DJ. Validation Study of a Quantitative multi-gene RT-PCR assay as a predictor of recurrence in stage II colon cancer patient. J Clin Oncol, 12, 4611-4619. 2011.
  7. Kerr DK and Midgley R. Defective Mismatch Repair in Colon Cancer: A prognostic or predictive biomarker? Journal of Clinical Oncology, 3210-3212, 2010.
  8. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr DJ. Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer, 9: 489-499. 2009.
  9. Huijbers A, Tollenaar RAEM, Pelt GWV, Zeestraten ECM, Dutton S, McConkey CC, Domingo E, Smit VTHBM, Midgley R, Warren BF and Kerr DJ The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the victor trial Annals of Oncology 24(1):179-185 2013
  10. Niedzwiecki D, Bertagnolli M, Warren S, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts SR, Porjosh GN , Kerr DJ, Fields, Goldberg< Mayer R, Colaccio TA Documenting the natural history of patients with resection of stage2 adenocarcinoma of the colon after randomisation to Edrocolomab or observation. . J Clin Oncol , 11, 2011:3146-3152
  11. Russo, A, Bazan V, Iacopetta B, Kerr, D, Sonssi T, Gebbia N. The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumour Site, Type of Mutation, and Adjuvant Treatment. Journal of Clinical Oncology. 23: 2005, 7518-7528.
  12. Midgley RS, Kerr DJ. Towards post-genomic investigation of colorectal cancer. Lancet, Feb 26; 355 (9205): 669-70 (2000)
  13. Danielsen HE, Pradhan M, Novelli M. Revisiting tumour aneuploidy – the place of ploidy assessment in the molecular era. Nat Rev Clin Oncol. 2015 Nov 24. doi: 10.1038/nrclinonc.2015.208.

References for ColoPredict

  1. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Almeida EG, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S, The CORGI Consortium, Thomas HJ, Maher E, Evans G, Lucassen A, Cummings C, Stevens M, Walker L, Halliday D, Armstrong R, Paterson J, Hodgson S, Homfray T, Side L, Izatt L, Donaldson A, Tomkins S, Morrison P, Goodman S, Brewer C, Henderson A, Davidson R, Murday V, Cook J, Haites N, Bishop T, Sheridan E, Green A, Marks C, Carpenter S, Broughton M, Greenhalge L, Suri M, The WGS500 Consortium, Steering Committee:, Donnelly P, Bell J, Bentley D, McVean G, Ratcliffe P, Taylor J, Wilkie A, Operations Committee:, Donnelly P, Broxholme J, Buck D, Cazier JB, Cornall R, Gregory L, Knight J, Lunter G, McVean G, Taylor J, Tomlinson I, Wilkie A, Sequencing & Experimental Follow-up:, Buck D, Gregory L, Humphray S, Kingsbury Z, Dat.a Analysis:, McVean G, Donnelly P, Cazier JB, Broxholme J, Grocock R, Hatton E, Holmes CC, Hughes L, Humburg P, Kanapin A, Lunter G, Murray L, Rimmer A, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ, McVean G, Houlston RS, Tomlinson I. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45(2):136-144. 2012.
  2. Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L, Kerr DJ, Dunlop MG, Tomlinson IP, Houlston RS The TERT variant rs2736100 is associated with colorectal cancer risk. British Journal of Cancer 107(6):1001-1008. 2012.
  3. La Thangue, NB and Kerr DJ. Predictive biomarkers: a shift towards personalised cancer medicine. Nature Reviews Clinical Oncology 8, 587-596. 2011.
  4. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, Spain SL, Broderick P, Domingo E, Farrington S, Prendergast JG, Pittman AM, Theodoratou E, Smith CG, Olver B, Walther A, Barnetson RA, Churchman M, Jaeger EE, Penegar S, Barclay E, Martin L, Gorman M, Mager R, Johnstone E, Midgley R, Niittymäki I, Tuupanen S, Colley J, Idziaszczyk S; COGENT Consortium, Thomas HJ, Lucassen AM, Evans DG, Maher ER; CORGI Consortium; COIN Collaborative Group; COINB Collaborative Group, Maughan T, Dimas A, Dermitzakis E, Cazier JB, Aaltonen LA, Pharoah P, Kerr DJ, Carvajal-Carmona LG, Campbell H, Dunlop MG, Tomlinson IP. Meta-analysis of three UK genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 42,973-77. 2010.
  5. Luis S, Spain S, Tomlinson I, Kerr D; Houlston R, Cazier J. Common variation at the Adiponectin locus is not associated with colorectal cancer risk in the United Kingdom. Human Molecular Genetics, 18, 1889-1892. 2008.
  6. Cogent Study Group Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genetics 40, 1426-35, 2008.
  7. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman A, Spain S , Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington S, Tenesa A, Prendergast J, Barnetson R, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R, Maher E, Lucassen A, Kerr D, Evans E, The CORGI Consortium, Schafmayer C, Buch S, Izke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen J, Hopper J, Southey M, Giles G, Severi G, Castellvı´-Bel S, Ruiz-Ponte C, Carracedo A, Castells A, The EPICOLON Consortium, Fo¨rsti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, WC Ho J, Cheng K, Sham P, Luk J, Agu´ ndez J , Ladero J, de la Hoya M, Calde´s T, Niittyma¨ki I, Tuupanene S, Karhu A, Aaltonen L, CazierJB, Campbell H, Dunlop M, & Houlston R. A genome-wide association study identifies novel colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics. 40, 623-630. 2008.
  8. Jaeger E, Webb E, Howart K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittma A, Kemp Z, Sullivan K, Heinimann K, Lubbe, Domingo E, Barclay E, Martin L, Gorman M, Chandler I, Vijayakrishna J, Wood, Papaemmanuil E, Penegar S, Qureshi M, members of the CORGI consortium, Tenesa A, Cazier JB, Kerr D, Gray R, Peto P, Dunlop M, Thomas HH, Houlston R, Tomlinson I. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nature Genetics, 40: 26-28, 2007.
  9. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr D, Gray R, Peto J, Cazier JP, Tomlinson I, Houlston R. A genome-wide association study shows that common alleles of : SMAD7: influence colorectal cancer risk. Nature Genetics 39, 1315 – 1317 (14 Oct 2007).
  10. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics 39, 984-988. 2007
  11. Dunlop MG, Tenesa A, Farrington SM, Ballereau S, Brewster DH, Koessler T,Pharoah P, Schafmayer C, Hampe J, Völzke H, Chang-Claude J, Hoffmeister M,Brenner H, von Holst S, Picelli S, Lindblom A, Jenkins MA, Hopper JL, Casey G,Duggan D, Newcomb PA, Abulí A, Bessa X, Ruiz-Ponte C, Castellví-Bel S, NiittymäkiI, Tuupanen S, Karhu A, Aaltonen L, Zanke B, Hudson T, Gallinger S, Barclay E,Martin L, Gorman M, Carvajal-Carmona L, Walther A, Kerr D, Lubbe S, Broderick P, Chandler I, Pittman A, Penegar S, Campbell H, Tomlinson I, Houlston RS. Cumulative impact of common genetic variants and other risk factors on colorectalcancer risk in 42,103 individuals. Gut. 2013 Jun;62(6):871-81. doi:10.1136/gutjnl-2011-300537. Epub 2012 Apr 5.

References for CancerNav and ColoNav

  1. La Thangue, NB and Kerr DJ. Predictive biomarkers: a shift towards personalised cancer medicine. Nature Reviews Clinical Oncology 8, 587-596. 2011.
  2. Susan Fotheringham, Mirjam T. Epping, Lindsay Stimson, Omar Khan, Victoria Wood, Francesco Pezzella, René Bernards, and Nicholas B. La Thangue Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis 66 Cancer Cell, 15, 57–66, January 6, 2009
  3. Khan O et al HR23B is a biomarker for tumor sensitivity to HDACinhibitor-based therapy. PNAS 6532–6537 , 107.(14) 2010
  4. New M, Olzscha H, Liu G, Khan O, Stimson L, McGouran J, Kerr D, Coutts A, Kessler B, Middleton M, La Thangue NB. A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death & Differ. 20, 1306-1316. 2013.
  5. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90(1):85-94. 2012.
  6. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol. 6(6):637-56. 2012.
  7. Gray, R, Barnwell J, McConkey C, Williams N and Kerr, DJ. QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group. Lancet, 370(9604):2020-9. 2007.
  8. Gray RG, Kerr DJ, McConkey CC, et al. On behalf of QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. The Lancet, 355, 1588-96 (2000).